Business Description
Lineage Cell Therapeutics Inc
NAICS : 541713
SIC : 2836
ISIN : US09066L1052
Description
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.9 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.12 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -3.76 | |||||
| Beneish M-Score | -2.41 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 118.3 | |||||
| 3-Year EBITDA Growth Rate | 5.2 | |||||
| 3-Year EPS without NRI Growth Rate | 6.2 | |||||
| 3-Year FCF Growth Rate | -8.6 | |||||
| 3-Year Book Growth Rate | -16.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -7.48 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.51 | |||||
| 9-Day RSI | 26.04 | |||||
| 14-Day RSI | 29.81 | |||||
| 6-1 Month Momentum % | -10.61 | |||||
| 12-1 Month Momentum % | -5.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.48 | |||||
| Quick Ratio | 2.48 | |||||
| Cash Ratio | 2.36 | |||||
| Days Sales Outstanding | 15.86 | |||||
| Days Payable | 1787.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.6 | |||||
| Shareholder Yield % | -10.72 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 95 | |||||
| Operating Margin % | -260.7 | |||||
| Net Margin % | -230.66 | |||||
| FCF Margin % | -265.55 | |||||
| ROE % | -29.71 | |||||
| ROA % | -19.52 | |||||
| ROIC % | -30.02 | |||||
| ROC (Joel Greenblatt) % | -482.45 | |||||
| ROCE % | -26.12 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 12.17 | |||||
| PB Ratio | 1.63 | |||||
| Price-to-Tangible-Book | 10.4 | |||||
| EV-to-EBIT | -4.23 | |||||
| EV-to-Forward-EBIT | -6.2 | |||||
| EV-to-EBITDA | -4.35 | |||||
| EV-to-Forward-EBITDA | -6.2 | |||||
| EV-to-Revenue | 11.02 | |||||
| EV-to-Forward-Revenue | 6.97 | |||||
| EV-to-FCF | -4.17 | |||||
| Price-to-Median-PS-Value | 0.11 | |||||
| Price-to-Net-Current-Asset-Value | 26 | |||||
| Price-to-Net-Cash | 52 | |||||
| Earnings Yield (Greenblatt) % | -23.64 | |||||
| FCF Yield % | -18.29 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lineage Cell Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 7.956 | ||
| EPS (TTM) (€) | -0.101 | ||
| Beta | 1.39 | ||
| Volatility % | 46.6 | ||
| 14-Day RSI | 29.81 | ||
| 14-Day ATR (€) | 0.051671 | ||
| 20-Day SMA (€) | 0.71375 | ||
| 12-1 Month Momentum % | -5.88 | ||
| 52-Week Range (€) | 0.464 - 1.32 | ||
| Shares Outstanding (Mil) | 220.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lineage Cell Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lineage Cell Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lineage Cell Therapeutics Inc Frequently Asked Questions
What is Lineage Cell Therapeutics Inc(STU:BT3)'s stock price today?
The current price of STU:BT3 is €0.52. The 52 week high of STU:BT3 is €1.32 and 52 week low is €0.46.
When is next earnings date of Lineage Cell Therapeutics Inc(STU:BT3)?
The next earnings date of Lineage Cell Therapeutics Inc(STU:BT3) is 2025-03-07 Est..
Does Lineage Cell Therapeutics Inc(STU:BT3) pay dividends? If so, how much?
Lineage Cell Therapeutics Inc(STU:BT3) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers